Targeting Oncogenic Nuclear Factor Kappa B Signaling with Redox-Active Agents for Cancer Treatment

Area of Science:

• Oncology
• Molecular Biology
• Biochemistry

Background:

• Nuclear factor kappa B (NF-κB) signaling is crucial in normal physiology but aberrant activation drives cancer growth and therapeutic resistance.
• Targeting NF-κB is essential for cancer treatment, but specificity is required to minimize side effects.
• Reactive oxygen species (ROS) are increasingly recognized as a promising therapeutic strategy in oncology.

Purpose of the Study:

• To explore the dual role of ROS in NF-κB signaling, both activating it at sublethal levels and inducing cancer cell apoptosis at high levels.
• To investigate combinatorial approaches using ROS-generating agents to enhance conventional cancer therapeutics.
• To evaluate the potential of targeting NF-κB signaling as a therapeutic niche in cancer treatment.

Main Methods:

• Review of current literature on NF-κB signaling, ROS generation, and cancer therapeutics.
• Analysis of the mechanisms by which ROS influence NF-κB activation and cancer cell cytotoxicity.
• Exploration of thiosemicarbazone-metal complexes as ROS-generating agents with antitumor activity.

Main Results:

• Cancer cells are more susceptible to ROS-induced cytotoxicity due to their higher baseline ROS levels.
• High ROS levels can induce apoptosis in cancer cells, presenting a therapeutic opportunity.
• Combinatorial therapy using ROS-generating agents may effectively reduce NF-κB activity and overcome treatment resistance.

Conclusions:

• Targeting NF-κB signaling with ROS-generating agents, such as thiosemicarbazones, offers a promising strategy for cancer therapy.
• These agents can induce potent antitumor activity by generating high ROS levels and upregulating metastasis suppressors like NDRG1.
• Developing combinatorial approaches that leverage ROS to inhibit NF-κB signaling can improve the efficacy of existing anticancer regimens.